Prof. dr. Bianca Rocca
Steering Committee
Faculty
Vice-Chair
b.rocca@tiscali.it
Rome, Italy
Bianca Rocca, MD, PhD is Associate Professor of Pharmacology at the Catholic University School of Medicine in Rome (Italy) and achieved the National Scientific Qualification for Full Professor in Pharmacology. She trained as Postdoctoral Fellow at the Center for Experimental Therapeutics, University Pennsylvania of Philadelphia (USA). She is Fellow of the European Society of Cardiology (FESC), has served as Chairperson of the European Society of Cardiology (ESC) Working Group on Thrombosis (2018-2020). She is currently Member of the board in the ESC Working Group on Cardiovascular Pharmacotherapy (2022-2026), member of the ESC Nominating Committed (2022-2024), of the ESC Committee for Practice Guidelines (2022-2024) and of the ESC sub-Committee for Scientific Documents (2022-2024).
She has been member of the Task Force of the 2018 ESC Guidelines on cardiovascular disease in pregnancy and of the Task Force of the 2019 ESC Guidelines on diabetes and of the 2022 EHA-ESC Guidelines on antithrombotic therapy in cancer patients with thrombocytopenia. She participated to several scientific and consensus scientific documents from the ESC Working Group on Thrombosis.
She is the co-Chair together with Prof. Hugo ten Cate of the Course of Advanced Antithrombotic Management.
She is member of the Editorial Board of: Diabetes and Vascular Disease Research, EHJ-Cardiovascular Pharmacology, Cardiovascular Drugs and Therapy, Frontiers in Drug Safety, European Journal of Preventive Cardiology.
She has co-authored over 150 articles in peer-reviewed journals including Annals of Internal Medicine, Blood, Clinical Pharmacology and Therapeutics, Circulation, EHJ, Diabetes, JACC, JCI, JTH, Nature Medicine, Science, PNAS (USA), Annals of Internal Medicine, with over 17,000 citations; H-index 52 (Google Scholar). Main scientific interests: antithrombotic drugs, eicosanoids, haemostasis, platelets, non-steroidal anti-inflammatory drugs, cardiovascular diseases, precision cardiovascular pharmacology.
